ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study
IMX-110 Surpasses Standard of Care in Mice Cancer Study Immix Biopharma, Inc. (NASDAQ:IMMX) IMX-110 produced a 50% response rate after...